Roche reported a strong 2025 with group sales growing by 7% at constant exchange rates, driven by robust demand for medicines and diagnostics. The Pharmaceuticals Division saw a 9% increase, with key drugs like Phesgo and Vabysmo leading growth. The Diagnostics Division achieved a 2% sales increase, despite challenges in China. Core operating profit rose by 13%, reflecting higher sales and efficiency improvements. Core earnings per share grew by 11%, and IFRS net income significantly increased by 58%. Several new drug approvals and positive clinical trial data, particularly for breast cancer and multiple sclerosis, highlight pipeline strength. Diagnostics also saw advancements with new tests for dengue and vaginitis. The company plans to increase its dividend for the 39th consecutive year. Looking ahead, Roche anticipates mid-single-digit sales growth and high-single-digit core EPS growth in 2026. A new board member with digital and technology expertise is proposed for election.